Crescent Biopharma, Inc. (CBIO)
18.54
+0.61
(+3.40%)
USD |
NASDAQ |
Sep 02, 16:00
18.51
-0.03
(-0.16%)
After-Hours: 20:00
Crescent Biopharma Enterprise Value : 348.44M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 348.44M |
| September 01, 2026 | 331.51M |
| August 31, 2026 | 294.59M |
| August 28, 2026 | 326.51M |
| August 27, 2026 | 326.79M |
| August 26, 2026 | 334.01M |
| August 25, 2026 | 305.70M |
| August 24, 2026 | 304.86M |
| August 21, 2026 | 309.86M |
| August 20, 2026 | 284.32M |
| August 19, 2026 | 314.58M |
| August 18, 2026 | 297.09M |
| August 17, 2026 | 319.02M |
| August 14, 2026 | 309.58M |
| August 13, 2026 | 295.43M |
| August 12, 2026 | 289.88M |
| August 11, 2026 | 297.09M |
| August 10, 2026 | 314.86M |
| August 07, 2026 | 301.26M |
| August 06, 2026 | 289.88M |
| August 05, 2026 | 271.56M |
| August 04, 2026 | 288.49M |
| August 03, 2026 | 246.58M |
| July 31, 2026 | 235.47M |
| July 30, 2026 | 250.74M |
| Date | Value |
|---|---|
| July 29, 2026 | 243.80M |
| July 28, 2026 | 290.15M |
| July 27, 2026 | 303.75M |
| July 24, 2026 | 286.27M |
| July 23, 2026 | 306.53M |
| July 22, 2026 | 273.22M |
| July 21, 2026 | 295.70M |
| July 20, 2026 | 251.57M |
| July 17, 2026 | 243.24M |
| July 16, 2026 | 253.24M |
| July 15, 2026 | 268.78M |
| July 14, 2026 | 258.65M |
| July 13, 2026 | 269.34M |
| July 10, 2026 | 315.13M |
| July 09, 2026 | 299.03M |
| July 08, 2026 | 300.42M |
| July 07, 2026 | 306.53M |
| July 06, 2026 | 304.59M |
| July 02, 2026 | 308.19M |
| July 01, 2026 | 307.92M |
| June 30, 2026 | 333.45M |
| June 29, 2026 | 312.67M |
| June 26, 2026 | 328.11M |
| June 25, 2026 | 284.83M |
| June 24, 2026 | 295.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Encompass Health Corp. | 15.49B |
| Myriad Genetics, Inc. | 404.09M |
| BioRestorative Therapies, Inc. | 1.582M |
| U.S. Stem Cell, Inc. | -- |
| Marijuana, Inc. | -13.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.84M |
| Total Expenses (Quarterly) | 24.84M |
| EPS Diluted (Quarterly) | -0.8135 |
| Earnings Yield | -41.25% |
| Normalized Earnings Yield | -41.25 |